Shares in Convatec (LON:CTEC) rallied to a one-year high after the medical products and technologies company raised FY26 revenue guidance. The upgrade reflects an acceleration in revenue growth in H2-to-date, with Convatec seeing strong demand for its essential consumables.
For the uninitiated, Convatec’s medical products and technologies help with the management of chronic conditions. The London-headquartered company is a market leader in advanced wound care, ostomy care, continence care and infusion care.
Its solutions provide a range of benefits, from infection prevention, treatment for hard to heal wounds, at-risk skin and ulcerated tissue, to supporting people with debilitating conditions.
Growth accelerates
For FY26, Convatec is now guiding for revenue growth in the 6.25% to 7% range, up from 5.5% to 6.5% previously. Encouragingly, the group remains on track to deliver a healthy adjusted operating profit margin of ‘at least 23%’.
In H2-to-date, the company has seen stronger growth in both Infusion Care and Continence Care, prompting management to upgrade FY26 guidance for both divisions.
In the 10 months to 31 October, Continence Care sales accelerated to mid-to-high single digit growth thanks to increased US new patient volumes and further strong growth outside the US.
Meanwhile, Infusion Care revenue has accelerated to double-digit growth year-to-date, driven by faster H2 diabetes growth and continued strong growth in AbbVie’s (NYSE:ABBV) treatment of Parkinson’s disease.
Forecasts for Convatec
| Year to December | FY25A | FY26E | FY27E |
| Revenue ($m) | 2,439 | 2,554 | 2,732 |
| Net profit ($m) | 175 | 394 | 444 |
| DPS (c) | 1.9 | 7.9 | 9.1 |
Source: Stockopedia
Year-to-date, Convactec’s Advanced Wound Care and Ostomy Care divisions are in growth. And in a show of confidence, the company reiterated its medium-term targets for 6% to 8% organic revenue and double-digit adjusted EPS (earnings per share) growth.
What did the CEO say?
CEO Jonny Mason said: ‘Revenue growth has accelerated in the second half, as we expected. We saw notable strength in Infusion Care, where improved execution enabled us to meet rising demand, ahead of new capacity coming online in 2027. Overall, we continued to gain share in all categories, underpinned by new product launches.’

Convatec is a FTSE 100 constituent which merits wider investor recognition, in our view. Supporting a growing cohort of people around the world with medical solutions for chronic conditions, the company is in rude health. And we think forecast risk remains skewed to the upside.
The company is investing to accelerate growth, supporting new product launches which are winning share with healthcare professionals and users.
We remain bullish on this progressive dividend payer. Convatec is well-positioned to deliver sustainable 6% to 8% top-line growth, which should translate into double-digit annual EPS (earnings per share) growth.




